A

Immunotherapy for atherosclerosis

Physiological Reviews, vol. 105, pp. 2141–2230

Abstract

Cardiovascular disease is the global number one cause of mortality and morbidity. The majority of cardiovascular diseases are caused by atherosclerosis, a lipid-driven, inflammatory disease of the middle- and large-sized arteries. The disease is characterized by the formation of atherosclerotic plaques throughout the arterial tree. Over the years, insights into the pathogenesis of atherosclerosis have shifted from a "lipid-driven" model to a "response-to-injury" perspective and more recently to a "lipid-driven inflammatory disease" viewpoint. We are now aware that a network of multiple immune cell types and subsets of the innate and adaptive immune system inhabit our arteries. Intricate interactions between these immune cell subsets, nonimmune cells, and local environmental substances such as lipids, cell debris, and calcium cause a fluidic balance of proinflammatory and regulatory responses. A dysregulation of this balance toward a proinflammatory milieu drives atherosclerotic disease progression. Although we have acknowledged that atherosclerosis is an inflammatory disease, state-of-the-art treatments are still based on lipid-lowering, antihypertensive, and lifestyle-changing strategies. In the past decade, clinical phase I, II, and III trials targeting the immune system revealed that patients tolerate immunotherapy, show decreased inflammation, and/or have a reduction in cardiovascular endpoints. However, the search for novel immunotherapeutic targets and treatment regimens as well as stratification of patients who would benefit from such treatments to combat atherosclerotic cardiovascular disease is only just beginning. In this review article, we will highlight the newest insights on the different cell subsets and components of the immune system in atherosclerosis and elaborate on current and future immunotherapeutics to treat atherosclerotic cardiovascular disease.

Authors 8

  1. University of Oxford

    Affiliation as printed

    OX3 7FY University of Oxford

  2. University of Virginia

    Affiliation as printed

    University of Virginia

  3. Bram Slütter Aachen

    Leiden University

    Affiliation as printed

    Leiden University

  4. Leiden University

    Affiliation as printed

    Leiden University

  5. University of Virginia

    Affiliation as printed

    University of Virginia

  6. Radboud University Medical Center · Eindhoven University of Technology

    Affiliation as printed

    Eindhoven University of Technology

    Radboud University Medical Center

  7. Lund University

    Affiliation as printed

    Lund University

  8. Esther Lutgens corresponding

    Mayo Clinic

    Affiliation as printed

    Mayo Clinic

Cited by 27 stored of 28

No patents citing this paper on Lens.org (checked 2026-10-11).

References 0